abstract |
The present invention relates to a pharmaceutical combination comprising an HMG-Co-A reductase inhibitor, in particular fluvastatin or pitavastatin or a pharmaceutically acceptable salt thereof and an mTOR inhibitor such as rapamycin or a rapamycin derivative. |